Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort

AIDS Research and Therapy

Volumn 9, Issue , 2012, Pages

  Lifson, Alan R ^a,b   Krantz, Elizabeth M ^a,b   Grambsch, Patricia L ^a,b   Macalino, Grace E ^b   Crum Cianflone, Nancy F ^b,c   Ganesan, Anuradha ^b,d   Okulicz, Jason F ^b,e   Eaton, Anne ^a   Powers, John H ^f   Eberly, Lynn E ^a,b   Agan, Brian K ^b   Banks, Susan ^g   Bavaro, Mary ^g   Chun, Helen ^g   Decker, Cathy ^g   Eggleston, Connor ^g   Fraser, Susan ^g   Hartzell, Joshua ^g   Hsue, Gunther ^g   Johnson, Arthur ^g   Kortepeter, Mark ^g   Lalani, Tahaniyat ^g   Landrum, Michael ^g   Linfesty, Michelle ^g   Merritt, Scott ^g   O'Connell, Robert ^g   Peel, Sheila ^g   Polis, Michael ^g   Ressnerk, Roseanne ^g   Tramont, Edmund ^g   Warkentien, Tyler ^g   Waterman, Paige ^g   Weintrob, Amy ^g   Whitman, Timothy ^g   Wortmann, Glenn ^g   Zapor, Michael ^g   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g NONE

Author keywords

CD4+ lymphocyte count; Highly active antiretroviral therapy; Mortality

Indexed keywords

HEPATITIS C ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SOLDIER; UNITED STATES;

EID: 84856802811     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-9-4     Document Type: Article

References (25)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-9. 10.1016/S0140-6736(03)13802-0, 12853195.
2. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006, 194:11-9. 10.1086/505147, 16741877.
3. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007, 146:87-95.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011, 1-167. Dept. Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents., http://www.aidsinfo.nih.gov/Contentfiles/AdultandAdolescentGL.pdf
5. Harris RJ, Sterne JA, Abgrall S, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008, 13:959-67.
6. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007, 21:2483-91. 10.1097/QAD.0b013e3282f09876, 18025885.
7. Jaen A, Esteve A, Miro JM, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 2008, 47:212-20. 10.1097/QAI.0b013e31815ee282, 18297762.
8. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009, 360:1815-26. 10.1056/NEJMoa0807252, 2854555, 19339714.
9. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010, 376:449-57. 10.1016/S0140-6736(10)60666-6, 3138328, 20638120.
10. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007, 21:685-92. 10.1097/QAD.0b013e32802ef30c, 17413689.
11. Marconi VC, Grandits GA, Weintrob AC, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther 2010, 7:14. 2894737, 20507622.
12. Centers for Disease Control 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Wkly Rep 1992, 41(RR-17):1-19. Centers for Disease Control.
13. Lifson AR, Krantz EM, Eberly LE, et al. Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. AIDS Res Ther 2011, 8:2. 3037838, 21244701.
14. When to Start Consortium Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009, 373:1352-63. 2670965, 19361855, When to Start Consortium.
15. The Antiretroviral Therapy Cohort Collaboration (ART-CC) Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009, 23:2199-208. 3122149, 19779320, The Antiretroviral Therapy Cohort Collaboration (ART-CC).
16. The HIV-CAUSAL Collaboration The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010, 24:123-37. 2920287, 19770621, The HIV-CAUSAL Collaboration.
17. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis 2008, 197:1145-55. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
18. Mugavero MJ, Napravnik S, Cole SR, et al. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis 2011, 53:927-35. 10.1093/cid/cir526, 21890751.
19. Zhao H, Goetz MB. Complications of HIV infection in an ageing population: challenges in managing older patients on long-term combination antiretroviral therapy. J Antimicrob Chemother 2011, 66:1210-14. 10.1093/jac/dkr058, 21421583.
20. Althoff KN, Gebo KA, Gange SJ, et al. CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. AIDS Res Ther 2010, 7:45. 3022663, 21159161.
21. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632-41.
22. Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008, 47:221-5. 10.1097/QAI.0b013e31815d2f59, 18223361.
23. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49(5 Suppl):S138-45.
24. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-6. 10.1001/jama.284.4.450, 10904508.
25. Sulkowski MS, Cheever LW, Spach DH. A guide for evaluation and treatment of hepatitis C in adults coinfected with HIV. 2011, U.S. Dept. Health and Human Services, Health Resources and Services Administration., http://hab.hrsa.gov/deliverhivaidscare/files/hepccoinfectguide2011.pdf